UPLOAD Filing
Rapport Therapeutics, Inc.
Date: July 7, 2025 · CIK: 0002012593 · Accession: 0000000000-25-007103
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288445
Letter
Re: Rapport Therapeutics, Inc. Registration Statement on Form S-3 Filed July 1, 2025 File No. 333-288445 Dear Abraham N. Ceesay:
July 7, 2025
Abraham N. Ceesay Chief Executive Officer Rapport Therapeutics, Inc. 99 High Street, Suite 2100 Boston, MA 02110
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Stephanie A. Richards
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> July 7, 2025 Abraham N. Ceesay Chief Executive Officer Rapport Therapeutics, Inc. 99 High Street, Suite 2100 Boston, MA 02110 Re: Rapport Therapeutics, Inc. Registration Statement on Form S-3 Filed July 1, 2025 File No. 333-288445 Dear Abraham N. Ceesay: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Stephanie A. Richards </TEXT> </DOCUMENT>